NASDAQ · Biotechnology

FULC (FULC) Stock

$3.87 -0.51% NASDAQ: FULC Healthcare

Valuation

MetricValue
Price$3.87
Market Cap$295.27M
P/E Ratio-5.17
P/B Ratio0.95
P/S Ratio0.00
EPS (TTM)$-1.18
52-Week High$15.74
52-Week Low$2.83
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-21.49%
ROA-20.49%
ROCE-24.36%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio27.46

Annual Financials (USD)

Metric20212022202320242025
Revenue$19.0M$6.0M$3.0M$80.0M$0
Operating Profit$-81.0M$-113.0M$-111.0M$-22.0M$-85.0M
Net Profit$-81.0M$-110.0M$-97.0M$-10.0M$-75.0M
EPS$-2.22$-2.35$-1.59$-0.16$-1.18
Op Margin-423.0%-1774.8%-3945.2%-27.4%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$235.0M$227.0M$258.0M$261.0M$366.0M
Total Liabilities$23.0M$28.0M$23.0M$18.0M$17.0M
Cash$35.0M$35.0M$26.0M$58.0M$198.0M
Borrowings$0$13.0M$11.0M$9.0M$6.0M

Latest News

Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit Simply Wall St. · Jun 27, 2026 A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring Simply Wall St. · Jun 5, 2026 Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks · Jun 5, 2026 FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End Zacks · Jun 3, 2026 JPMorgan Downgrades Fulcrum Therapeutics to Underweight From Overweight MT Newswires · Jun 3, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-78.0M$-97.0M$-91.0M$-2.0M$-60.0M
Investing Cash Flow$-131.0M$10.0M$-37.0M$32.0M$30.0M
Financing Cash Flow$4.0M$4.0M$1.0M$0$0
Net Cash Flow$-22.0M$0$-10.0M$33.0M$139.0M
Free Cash Flow$-80.0M$-99.0M$-91.0M$-2.0M$-60.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-18.90%
Quick Ratio34.33
Interest Coverage—
Return 1Y-52.47%
Return 3Y0.53%
Return 5Y-61.65%

Ownership

Insiders Held3.83%
Institutions Held126.06%
Institutions Float Held131.08%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC6,561,1112026-03-31
RA Capital Management, L.P.6,053,9602026-03-31
Blackrock Inc.5,390,5932026-03-31
TCG Crossover Management, LLC5,250,0002026-03-31
Braidwell LP 3,134,9222026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCT $1.24 +5.98% -1.58 $157.72M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CMPX $2.31 -3.35% -4.71 $416.00M 0.00%
LCTX $1.08 -1.82% -17.61 $269.24M 0.00%
LXRX $2.19 -2.67% -15.93 $972.79M 0.00%

About FULC

FULC is led by CEO Alexander C. Sapir, employs 45 people, headquartered in US, publicly traded since 2019.

FULC stock trades at $3.87 with a market capitalization of $295.27M. The stock is valued at a price-to-earnings (P/E) ratio of -5.17, price-to-book of 0.95, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.83 and $15.74, and currently trades 75.4% below its 52-week high.

On profitability, FULC generates a return on equity (ROE) of -21.49%, return on capital employed of -24.36%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides